Key Drivers
- High gross margin
- Negative free cashflow
- Rising valuation multiples
AIAI Summary
TWST is shifting from a pure volume/burn story to a margin- and platform-monetization thesis—if management delivers sustained >50% gross margins and clear, quarter-by-quarter free-cash-flow improvement (and reduces the ~$5M data-business drag), the stock becomes a buy-on-confirmation; failure to hit those milestones or loss of large customers would quickly compress the elevated valuation and force dilution. Monitor gross-margin mix, FCF trajectory, and progress on the planned spin-off as the specific, actionable signals to validate the investment case.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Negative free cashflow
- •Rising valuation multiples
Twist combines strong gross margins, ample liquidity and low leverage with worsening profitability, deeply negative free cash flow, shrinking cash balances and rising valuation multiples that increase investment risk.
Price Behavior
Key Price Behavior Insights:
- •Below last month
- •Support tested
- •Resistance intact
TWST is in a short-term downtrend at $42.07 (below its last month average) after a ~13% drop that broke the $45–$49 congestion, with $42–$43.5 as tentative support and $48–$50 as key resistance—break below ~$42 would worsen the outlook.
~13% decline from ~$48.6 to $42.07 with increased daily volatility
Sentiment & News
Key News Insights:
- •Divergent ownership
- •Near-term volatility
- •Active analyst coverage
Institutional positioning in Twist Bioscience is mixed—Artisan upped its stake while Citigroup cut back—accompanied by near-term share weakness, analyst attention, and ongoing management investor engagement.
Mixed institutional moves and conference engagement suggest continued stock sensitivity to earnings/updates and potential for short-term trading volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings